NEW YORK, October 28, 2020 – Proskauer, a leading international law firm, today announced that its client, Eucrates Biomedical Acquisition Corp. (the "Company"), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, closed its initial public offering of 10,000,000 units at an initial public offering price of $10.00 per unit.

The offering was led by joint book-running managers Stifel and H.C. Wainwright & Co. and the Company’s securities trade on The Nasdaq Capital Market.

While the Company may pursue an initial business combination target in any business or industry, it intends to focus on the biomedical and healthcare industry. The Company intends to target North American and European healthcare companies with the potential to drive transformational change through the convergence of biomedicine and data science.

Proskauer lawyers Daniel Forman, Aaron Quint and Luisa Ewing acted on this transaction.

About Proskauer

We are 725+ lawyers serving clients from 12 offices located in the leading financial and business centers in the Americas, Europe and Asia. The world’s leading organizations, companies and corporations choose us to be their representatives in their most critical situations.  But more, they consider Proskauer a strategic partner to drive their business forward.  We work with asset managers, major sports leagues, Fortune 500 companies, entertainment industry legends and other industry-redefining companies.